21 Jul 2025
Princeton, New Jersey, November 19, 2018 – RxLogix Corporation, a global leading provider of Safety and Pharmacovigilance (PV) Software and Services, today announced the signing of an agreement with Booz Allen Hamilton to support the implementation of PV Signal and PV Reports at the US Food and Drug Administration (FDA). The FDA is responsible for protecting the public health by ensuring...
21 Jul 2025
Princeton, New Jersey, November 10, 2021 – RxLogix Corporation, a global leading provider of end-to-end Safety and Pharmacovigilance (PV) Software and Services, today announced the Go-Live of FAERS II at the United States Food and Drug Administration (FDA). FAERS II utilizes the RxLogix integrated PV signaling platform consisting of PV Signal, PV Reports, and PV Analytics. The CDER & CBER at...
21 Jul 2025
Amsterdam, Netherlands, December 7th 2023 — RxLogix Corporation, a global leading provider of end-to-end Safety and Pharmacovigilance (PV) Software and Services, is delighted to announce a strategic software agreement with the European Medicines Agency (EMA) to begin the development of the new Signal and Safety Analytics (SSA) platform. The SSA platform, which will include RxLogix PV Signal, PV Reports and...
RxLogix provides industry's best solutions to the ever-changing drug safety & pharmacovigilance
Request DemoSubscribe to our newsletter and learn the latest news from RxLogix.
Sign Up
